Effect of Erythropoietin-stimulating agent on uremic neuropathy in hemodialysis patients: a single-center open-label prospective study

Table 2 Effect of ESA therapy on some of neurophysiological findings in non-diabetic patients in comparison to those of diabetic patients

Nerve (n = 6)	0_c	3_c	p	Nerve (n = 4)	0_D	3_D	P
Median (n = 6)				Median (n = 4)
MNCV	53.08 ± 3.51	50.48 ± 4.88	0.099	MNCV	42.15 ± 1.93	42.52 ± 3.93	0.559
CMAP	6.98 ± 2.55	5.27 ± 2.56	0.170	CMAP	4.45 ± 0.68	5.5 ± 1.69	0.228
Ulnar (n = 6)				Ulnar (n = 4)
MNCV	47.25 ± 4.02	53.35 ± 3.57	0.050	MNCV	41.3 ± 9.13	43.03 ± 3.97	0.267
CMAP	5.38 ± 2.32	7.77 ± 2.14	0.050	CMAP	6.85 ± 1.49	6.8 ± 1.99	0.881
Median (n = 5)*				Median (n = 2)*
SNCV	48.92 ± 5.12	51.54 ± 2.63	0.325	SNCV	40.5 ± 1.41	41.1 ± 1.27	0.105
Ulnar (n = 5)*				Ulnar (n = 2)*
SNCV	45.54 ± 2.99	49.52 ± 7.72	0.351	SNCV	40.7 ± 14.57	38.95 ± 23.6	0.523
Radial (n = 5)*				Radial (n = 2)*
SNCV	47.98 ± 4.63	53.5 ± 3.67	0.018	SNCV	45.75 ± 15.9	45.45 ± 8.41	0.426

0 baseline finding in non-diabetic patients, 3 finding 3 months after dialysis and treatment with ESA in non-diabetic patients, MNCV motor nerve conduction velocity in m/s, CMAP compound motor action potential amplitude in mv, SNCV sensory nerve conduction velocity in m/s. *These drops in records are attributed to technical difficulties (ulcers, edema or AV fistula) in the tested side at one or the 2 sessions. Ulnar MNCV, CMAP and Radial SNCV showed statistically significant improvement in group C